Celyad Oncology S.A. Celyad Oncology S.A.

Celyad Oncology S.A.

CYAD

Helyezés a részvények között #31686
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to... Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
Részvényárfolyam
$0.24909259
Piaci kapitalizáció
$11.77M
Változás (1 nap)
1.94%
Változás (1 év)
-47.00%
Ország
BE
Kereskedés Celyad Oncology S.A. (CYAD)

Kategória

Healthcare
Celyad Oncology S.A. (CYAD) osztalékhozamának története
Celyad Oncology S.A. (tőzsdei szimbólum: CYAD) osztalékhozama (TTM) 2026 állapot szerint: 0
Átlagos osztalékhozam az elmúlt 5 évben: 0.00%
Celyad Oncology S.A. (CYAD) osztalékhozamainak története 2026 és 2026 között
Éves záró osztalékhozam (TTM)
Év Osztalékhozam Változtassa meg
Nincs elég adat a megadott dátumokhoz.
Hasonló cégek vagy versenytársak osztalékhozamai (TTM)
Vállalat Osztalékhozam Ország
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.17%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL